上海医药：替格瑞洛片获得美国FDA批准文号

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Changzhou Pharmaceutical Factory, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ticagrelor tablets, which are used to reduce the incidence of thrombotic cardiovascular events in patients with acute coronary syndrome [1] Company Summary - The approved drug, Ticagrelor, was originally developed by AstraZeneca and was launched in the U.S. in 2011 [1] - As of the date of the announcement, the company has invested approximately RMB 9.6713 million in research and development for this drug [1]